Evidence map›Paper›PMID 27885435›Full record

ArticleClinical & experimental metastasis2017

Comparison of immunophenotypes of primary breast carcinomas and multiple corresponding distant metastases: an autopsy study of 25 patients.

B Szekely, Zs I Nagy, Zs Farago, O Kiss, G Lotz, K A Kovacs, L Madaras, N Udvarhelyi, M Dank, Gy Szentmartoni and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & experimental metastasis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Clinical, pathological and gene expression profiling of estrogen receptor discordance in breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

B Szekely2nd Department of Pathology, Semmelweis University, Budapest, Hungary. szekelybora@gmail.com.ORCID 0000-0002-0387-7516
Zs I Nagy2nd Department of Pathology, Semmelweis University, Budapest, Hungary.
Zs Farago2nd Department of Pathology, Semmelweis University, Budapest, Hungary.
O Kiss2nd Department of Pathology, Semmelweis University, Budapest, Hungary.
G Lotz2nd Department of Pathology, Semmelweis University, Budapest, Hungary.
K A Kovacs2nd Department of Pathology, Semmelweis University, Budapest, Hungary.
L Madaras2nd Department of Pathology, Semmelweis University, Budapest, Hungary.
N UdvarhelyiSurgical and Molecular Tumour Pathology Centre, National Institute of Oncology, Budapest, Hungary.
M DankDivision of Oncology, Semmelweis University, Budapest, Hungary.
Gy SzentmartoniDivision of Oncology, Semmelweis University, Budapest, Hungary.
Zs Baranyai1st Department of Surgery, Semmelweis University, Budapest, Hungary.
L Harsanyi1st Department of Surgery, Semmelweis University, Budapest, Hungary.
A M Tőkés2nd Department of Pathology, Semmelweis University, Budapest, Hungary.
Jozsef Timar2nd Department of Pathology, Semmelweis University, Budapest, Hungary.
A M Szasz2nd Department of Pathology, Semmelweis University, Budapest, Hungary.
J Kulka2nd Department of Pathology, Semmelweis University, Budapest, Hungary.
Semmelweis University · HUNational Institute of Oncology · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phenotypical change in metastatic breast carcinoma has widely been accepted as an inherent biological feature rather than technical fault. We analyzed the immunohistochemical phenotype and histopathological features of 25 primary breast carcinomas and 90 corresponding distant metastases in 23 organs retrospectively. Histological slides were reviewed for prognostic and predictive factors. Overall, metastases were more similar to each other and often differed from the primary tumor. We created a 3-step grouping system based on the localization of metastases. Regions: tumors metastasizing to the abdominal region were likely to lose ER (p = 0.002); we detected loss of PR in metastases to the thorax (p = 0.039) and abdomen (p < 0.001). Organ systems: loss of ER and PR was observed in metastases to the gastrointestinal system (p = 0.026 and p = 0.001, respectively), in the respiratory system only the loss of PR was significant (p = 0.05). Individual organs: the primaries were likely to lose the hormone receptors in liver metastases (ER p = 0.026; PR p = 0.004). In lung metastases only loss of PR was apparent (p = 0.049). We did not observe significant change in HER2 status, regarding Ki67 change occurred only in bone metastases compared to the primary (p = 0.048). 7/25 patients' distant metastases had heterogeneous immunoprofiles. The later the metastasis was discovered the more likely it had a differing IHC profile compared to the primary tumor, patients who had longer OS had a higher chance to develop a discordant metastasis. Immunoprofile of metastases may differ from primary breast cancer and from each other, probably resulting in different response to therapy.

Indexed as

AdultAgedAutopsyBone NeoplasmsBreast NeoplasmsCarcinomaFemaleHumansImmunophenotypingLiver NeoplasmsLung NeoplasmsMiddle AgedNeoplasm MetastasisPrognosisAutopsyBreast cancerImmunophenotypeMetastasisSubtypeSurvival

Identifiers

PMID27885435
OpenAlexW2556832036

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.